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CXCR7 influences leukocyte entry into the
CNS parenchyma by controlling abluminal
CXCL12 abundance during autoimmunity
Lillian Cruz-Orengo,1 David W. Holman,1 Denise Dorsey,1 Liang Zhou,5,6
Penglie Zhang,7 Melissa Wright,1 Erin E. McCandless,2 Jigisha R. Patel,1
Gary D. Luker,8,9 Dan R. Littman,10,11 John H. Russell,3
and Robyn S. Klein1,2,4

Loss of CXCL12, a leukocyte localizing cue, from abluminal surfaces of the blood–brain
barrier occurs in multiple sclerosis (MS) lesions. However, the mechanisms and consequences of reduced abluminal CXCL12 abundance remain unclear. Here, we show that
activation of CXCR7, which scavenges CXCL12, is essential for leukocyte entry via endothelial barriers into the central nervous system (CNS) parenchyma during experimental autoimmune encephalomyelitis (EAE), a model for MS. CXCR7 expression on endothelial barriers
increased during EAE at sites of inflammatory infiltration. Treatment with a CXCR7 antagonist ameliorated EAE, reduced leukocyte infiltration into the CNS parenchyma and
parenchymal VCAM-1 expression, and increased abluminal levels of CXCL12. Interleukin 17
and interleukin 1 increased, whereas interferon- decreased, CXCR7 expression on and
CXCL12 internalization in primary brain endothelial cells in vitro. These findings identify
molecular requirements for the transvascular entry of leukocytes into the CNS and suggest
that CXCR7 blockade may have therapeutic utility for the treatment of MS.
CORRESPONDENCE
Robyn S. Klein:
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Abbreviations used: BBB,
blood–brain barrier; BMEC,
brain microvessel endothelial
cell; CNS, central nervous system; EAE, experimental autoimmune encephalomyelitis;
EGFP, enhanced GFP; ES,
embryonic stem; GFAP, glial
fibrillary acidic protein; GPCRs,
G-protein coupled receptors;
IHC, immunohistochemical;
MOG, myelin oligodendrocyte
glycoprotein; MS, multiple
sclerosis; QPCR, quantitative
RT-PCR

Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disease of the central
nervous system (CNS) characterized by the
pathological infiltration of autoreactive leukocytes (Frohman et al., 2006; Man et al., 2007;
McFarland and Martin, 2007). Studies examining the migratory routes of encephalitogenic
T cells recently established that they invade
the submeningeal CNS via perivascular scanning along transvascular pathways that originate within the meninges (Bartholomäus et al.,
2009). These cells remain perivascularly localized until arriving at Virchow-Robin spaces,
where access to the CNS parenchyma is accomplished via migration across astrocytic endfeet
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that comprise the glial limitans (Abbott et al.,
2006). Restriction of leukocyte entry is thus
normally accomplished via the presence of localizing cues along perivascular spaces (Körner
et al., 1997; Vajkoczy et al., 2001; McCandless
et al., 2006, 2008b); however, in MS this regulation is lost and cells gain inappropriate access to
the CNS parenchyma. Recent data examining the blood–brain barrier (BBB) expression
of CXCL12, a chemokine that restricts the
CNS entry of CXCR4-expressing leukocytes
(McCandless et al., 2006, 2008b), indicate that
its loss from abluminal surfaces within the CNS
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compartments determined that IL-17 and IFN- exhibit antagonistic effects on this process via regulation of CXCR7
expression at the mRNA level. CXCR7 appears to play an
essential role in controlling abluminal expression of CXCL12,
which is necessary to prevent pathological entry of immune
cells into the CNS parenchyma, and is therefore an attractive
pharmacologic target for therapeutic treatment of MS.
RESULTS
CXCR7 is expressed exclusively by the CNS vasculature
during CNS autoimmunity
In prior studies, we observed that CXCL12 internalization
within CNS postcapillary venules occurred specifically in specimens derived from individuals with CNS autoimmune disease
(McCandless et al., 2006, 2008a). Given the recent discovery
that CXCR7 mediates CXCL12 internalization within mammalian cells (Naumann et al., 2010), we analyzed spinal cord
tissues of mice in which one copy of the CXCR7 gene was
replaced with cDNA encoding enhanced GFP (EGFP;
CXCR7GFP/+). In the mutated locus, the EGFP gene replaces
the entire open reading frame encoding exon 2 in CXCR7
(Fig. S1). GFP expression in naive CXCR7GFP/+ mice was observed throughout the meninges and microvasculature (Fig. 1,
a and b) and was increased at postcapillary venules during EAE
induced by adoptive transfer of myelin oligodendrocyte glycoprotein (MOG)–specific T cells (Fig. 1, c–e). GFP colocalized
with CD31 in specimens from both naive mice and from those
with EAE (Fig. 1, f and g). Inflammatory infiltrates were completely devoid of GFP expression (Fig. 1, c-e, h) even after amplification with anti-GFP antibodies (Fig. 1, g and h). Analyses
of mean numbers of GFP+ venules (Fig. 1 i) and levels of GFP
expression (Fig. 1 j) within white matter regions of CXCR7GFP/+
mice revealed increases in spinal cord (P = 0.04) tissues, but not
cerebellar and brainstem tissues, of mice with adoptive transfer
EAE compared with naive animals. Baseline numbers of GFP+
venules in the brainstem, however, were significantly higher
than in the spinal cord (P = 0.0062), reflecting the long known
increased vascularity of gray matter areas within the CNS
(Craigie, 1920). Flow cytometric analysis of GFP levels within
leukocytes derived from secondary lymphoid tissues of MOGimmunized wild-type and CXCR7GFP/+ detected GFP within
a small population of CD19+ cells, but not in CD4+, CD8+,
CD11b+, or CD11c+ cells (Fig. 1 k). Approximately 11 and 4%
of CD19+ cells exhibited GFP expression in splenic and lymph
node tissues, respectively, of MOG-immunized mice (Fig. 1 l).
No GFP expression was observed in any leukocytes in un
immunized mice (not depicted). Collectively, these data suggest
that CXCR7 is expressed at endothelial cell barriers within the
CNS and that this expression is increased in EAE at sites of
inflammatory infiltration.
CXCR7 antagonism ameliorates EAE and decreases
leukocyte entry into the CNS parenchyma
Given the predominance of CXCR7 expression on the CNS
vasculature and its increase in the setting of CNS autoimmune
CXCR7 controls leukocyte trafficking into CNS | Cruz-Orengo et al.
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is specific to MS (McCandless et al., 2008a,b). Polarized
CXCL12 expression at the BBB therefore appears to be an
important component of CNS immune privilege, whereas
loss of CXCL12 polarity is associated with leukocyte entry.
The mechanisms responsible for altered CXCL12 expression
at the CNS microvasculature are unknown; however, studies
using the murine model of MS, experimental autoimmune
encephalomyelitis (EAE), implicate several T cell cytokines
including IL-1, TNF, IFN-, and IL-17 in leukocyte entry
across the CNS endothelium (Argaw et al., 2006; Afonso
et al., 2007; Kebir et al., 2007; Lees et al., 2008; McCandless
et al., 2009; Huppert et al., 2010), suggesting they may influence localizing cues at this site.
Recently, CXCR7 (formerly RDC-1) has been identified as an alternative receptor for CXCL12 that also binds
CXCL11 (Burns et al., 2006). CXCR7 possesses homology
with conversed domains of G protein–coupled receptors
(GPCRs; Libert et al., 1990) and is structurally similar to other
CXC receptors, although ligand binding does not initiate
typical intracellular signal transduction, but instead results
in -arrestin recruitment and MAP kinase activation (Zabel
et al., 2009; Rajagopal et al., 2010). CXCR7 expression studies have identified protein on the surface of B cells (Infantino
et al., 2006; Sierro et al., 2007) and transcripts within the
heart, kidney, and spleen (Burns et al., 2006) and in the adult
CNS, within hippocampal neurons and extensively along the
microvasculature (Schönemeier et al., 2008a). Studies in
zebrafish development and in in vitro mammalian systems
suggest CXCR7 functions primarily to sequester CXCL12
(Boldajipour et al., 2008; Mahabaleshwar et al., 2008;
Naumann et al., 2010), thereby regulating signaling through
CXCR4. No studies, however, have explored in vivo roles for
CXCL12 sequestration within mammals in either physiological or diseased states. The coexpression of this chemokine/
receptor pair at the CNS microvasculature suggests a potential
mechanism for regulating CXCL12 localization along abluminal surfaces, and therefore immune privilege at the BBB.
In this study, we provide the first report of the role of
CXCR7 in an in vivo disease model and provide insight into
the mechanism of CXCL12 internalization at the BBB.
We examined the expression and activity of CXCR7 in CNS
tissues, using both in vivo and in vitro model systems. The
results described here demonstrate that CXCR7 is critical in
mediating CXCL12 internalization at CNS endothelial barriers in the autoimmune model EAE. In vivo antagonism of
CXCR7 inhibited induction of EAE in a dose-dependent
manner, while ameliorating ongoing disease. Compared with
vehicle-treated animals, mice treated with CXCR7 antagonist were found to have decreased parenchymal and perivascular infiltrates, with accumulation of immune cells within
the subarachnoid space, adjacent to meningeal vessels. Vehicletreated mice with EAE showed attenuated abluminal CXCL12
expression, whereas EAE mice treated with high doses of
antagonist retained perivascular CXCL12 expression pattern. Studies evaluating the impact of T cell cytokines on
CXCR7-mediated sequestration of CXCL12 into lysosomal
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animals treated with vehicle alone beginning at the time of
adoptive transfer. Disease expression in adoptively transferred
animals treated with vehicle was no different from similarly
transferred animals that remained untreated (not depicted).
The mean maximal disease severity scores of all groups of
CCX771-treated versus vehicle-treated were also significantly
lower (P < 0.001) and differences in disease and weight loss
curves between groups of animals treated with 10 and
30 mg/kg doses of CCX771 were also significant (P < 0.001;
Fig. 2, b and c).
Given that the CXCR7 antagonist CCX771 reduced
clinical disease severity when administered at the time of
adoptive transfer of MOG-specific T cells, we wondered
whether CXCR7 antagonism could treat ongoing EAE.
Thus, we compared treatment with vehicle alone with treatment with vehicle until day 9 after transfer, when animals
have attained a score of 1, and then began treatment with
10 mg/kg of CCX771. We found that CCX771 significantly
reduced the clinical severity of peak disease and improved the
recovery of diseased animals compared with vehicle-treated

Figure 1. CXCR7 is expressed by endothelial cells within the CNS and B cells within lymphoid tissues. Spinal cord sections derived from naive
CXCR7GFP/+ mice (a, b, and f) and from those with EAE (c–e, g, and h) were evaluated via confocal microscopy for GFP fluorescence alone (green; a–d) or
with expression of CD45 (red; e) and, after amplification with anti-GFP antibodies, in conjunction with detection of CD31 (f and g) and CD45 (h). All nuclei
are counterstained with ToPro3 (blue). Bars, 25 µm. Quantitation of mean numbers of GFP+ venules (i) and mean GFP levels (j) in spinal cord (SC), brainstem (BS), and cerebella (CB) of naive or EAE CXCR7GFP/+ mice are shown. Data are expressed as the mean intensity per vessel for n = 12 images taken
from 3 mice/group. *, P < 0.01. Flow cytometric analysis of expression of GFP and leukocyte markers in cells derived from spleens (top) and lymph nodes
(LNs, bottom) of MOG-immunized wild-type (red lines) and CXCR7GFP/+ (black lines) mice (k). (l) Spleen and LN cells were stained with indicated antibodies;
numbers indicate percentages of CD19+ cells expression GFP. Data are representative of two experiments with three mice per group.
JEM VOL. 208, February 14, 2011
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disease, we hypothesized that CXCR7 would impact on the
localization of infiltrating immune cells via loss of CXCL12
as a localizing cue within perivascular locations. Accordingly,
disruption of this process might allow abluminal CXCL12 to
persist, preventing perivascular leukocytes from gaining access
to the CNS parenchyma.To test this, we administered various
doses of a small molecule inhibitor of CXCR7, CCX771,
daily to mice beginning at the time of adoptive transfer of 107
MOG-specific CD4+ T cells and continued throughout the
course of clinical disease. CCX771 exhibits high affinity for
human and mouse CXCR7 (11 nM; Zabel et al., 2009) and
is completely selective relative to all other chemokine, chemo
tactic, and nonchemokine GPCRs tested (>10 µM; Tables
S1 and S2). Subcutaneous, daily administration of CCX771 at
the doses used in our studies results in high systemic exposure
with a serum half-life of 6 h (Fig. S2 a) and efficient penetration into the CNS, as determined by LC-MS (Carbajal et al.,
2010). Administration of CCX771 at doses of 5, 10, and
30 mg/kg led to a dose-dependent decrease in clinical disease
severity (Fig. 2 a) and weight loss (Fig. 2 b) compared with
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animals, even if CCX771 treatment began when all animals
had reached a score of 1 (P = 0.0146; Fig. 2 d). Analysis of
weight loss in both groups also revealed a significant difference between vehicle and the antagonist treated groups (P <
0.001; Fig. 2 e), as did analysis of mean maximal disease severity scores (Fig. 2 f). These data strongly implicate CXCR7 as
a disease-modifying molecule.
CXCR7 antagonism prevents leukocyte entry
at the microvasculature
To examine the basis of our clinical findings, we analyzed spinal cord tissues from animals with EAE that had undergone
no treatment, treatment with vehicle or with various doses of
CCX771. Histological examination of spinal cord sections
from vehicle- and CCX771-treated (10 mg/kg) mice with
EAE at the peak of their relative disease curves (12 d after
transfer), revealed dramatic differences in the extent of meningeal and parenchymal inflammatory white matter lesions,
whereas animals treated with high dose CCX771 (30 mg/kg)
exhibited no meningeal or parenchymal infiltrates (Fig. 3 a).
Similarly, luxol fast blue (LFB) analysis of spinal cord tissues
revealed decreased demyelination in mice treated with 10 or
30 mg/kg of CCX771 compared with vehicle-treated animals (Fig. S2 b).To assess the differences in meningeal inflammation between treatment groups, we used the astrocyte
activation marker glial fibrillary acidic protein (GFAP) to delineate the edge of the parenchyma.
Immunohistochemical (IHC) detection of VCAM-1 and
GFAP in mice treated with vehicle versus CCX771 during
adoptive transfer of MOG-specific T cells revealed that mice
treated with 10 mg/kg CCX771 exhibited marked increases
in numbers of cell localized to the meninges compared with
vehicle-treated mice and to mice treated with 30 mg/kg
330

CCX771, which did not exhibit any meningeal inflammation
(Fig. 3 b). In addition, detection of VCAM-1 and GFAP in
mice treated with vehicle versus CCX771, regardless of dose,
revealed meningeal VCAM-1 expression in all animals, but no
parenchymal VCAM-1 expression in mice that received antagonist, despite similar levels of GFAP+ expression in all mice
(Fig. 3 b). Analysis of the overall width of meningeal infiltrates
in 10 consecutive images under high power magnification revealed significant increases in mice treated with 10 or 5 mg/kg
CCX771 versus mice treated with vehicle or left untreated
(P = 0.0003 and 0.0243, respectively; Fig. 3 c). Quantitative
assessment of the numbers of perivascular cuffs (designated as
“lesions”) per 10 consecutive high power fields in each section revealed significantly fewer lesions in mice treated with
CCX771 at 10 mg/kg versus nontreated or vehicle-treated
mice (P = 0.0114; Fig. 3 d). Analysis of numbers of leukocytes
within perivascular cuffs observed in spinal sections from all
treatment groups showed that CXCR7 antagonism led to
significantly fewer lesions with extensive cuffing (P = 0.0021,
score 2; P = 0.0142, score 3; Fig. 3 e).
IHC identification of subsets of infiltrating leukocytes
revealed many CD3+ and CD11b+ cells within the meninges
of mice with EAE treated with vehicle or with 10 mg/kg of
CCX771, whereas mice treated with 30 mg/kg of CCX771
exhibited almost no CD3+ and CD11b+ cells at this location
(Fig. 4 a). Few B220+ cells were observed within the meninges of either vehicle or CCX771-treated animals (Fig. 4 a).
Although vehicle-treated mice exhibited infiltration of CD3+
and CD11b+ cells within the parenchyma, mice treated with
10 mg/kg CXCR7 antagonist exhibited predominantly
CD11b+ cell parenchymal infiltration, whereas both CD3+
and B220+ cells accumulated within the meninges (Fig. 4 a).
Analysis of leukocyte subsets within deep white matter
CXCR7 controls leukocyte trafficking into CNS | Cruz-Orengo et al.
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Figure 2. CXCR7 antagonism decreases
the clinical severity of EAE. Mice were intravenously injected with 10 × 106 MOGspecific CD4+ T cells, and dose response
effects of CCX771 on disease induction (a–c)
and treatment of ongoing disease (d–f) were
examined. For dose-response curves evaluating clinical disease severity and weight loss
(a and b), animals were grouped into those
receiving vehicle or CCX771 at indicated doses
daily, beginning at the time of adoptive transfer of MOG-specific CD4+ T cells. Mice were
monitored daily, weighed, and graded on a
scale of 0–5, as described previously
(McCandless et al., 2009). Numbers in parentheses indicated number of mice with disease
compared with total mice in each group. Results are expressed as mean disease scores ±
SEM, and curves were analyzed using oneway ANOVA compared with vehicle–treated mice. **, P < 0.001. (c) Mean maximal disease severity scores for animals treated with vehicle or CCX771 at
indicated doses. *, P < 0.05; **, P < 0.01; ***, P < 0.001. To determine whether CCX771 ameliorates ongoing EAE and weight loss (d and e), animals were
grouped into those receiving vehicle or vehicle until animals reached a score of 1 and then CCX771 at 10 mg/kg. Results are expressed as mean disease
scores ± SEM and analyzed via one-way ANOVA. **, P < 0.001. (f) Mean maximal disease severity scores for animals treated with vehicle or with vehicle
until development of disease and then CCX771 at 10 mg/kg. **, P < 0.01. Data are representative of five experiments with n = 10–13 animals per group.
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perivascular cuffs of vehicle versus CCX771-treated mice
with EAE revealed a dose-dependent decrease in the numbers
of infiltrating CD3+ (P = 0.0158, 10 mg/kg; P = 0.0068,
30 mg/kg), CD11b+ (P = 0.0124, 10 mg/kg; P = 0.0033,
30 mg/kg), and B220+ (P < 0.0001, 30 mg/kg) cells (Fig. 4,
b and c). Consistent with this, the majority of TNF expression
was detected primarily within the meninges in CCX771treated mice, whereas vehicle-treated mice also exhibited
TNF expression in the parenchyma (Fig. 4 d). Collectively,
these data suggest that CXCR7 antagonism is associated with
loss of parenchymal VCAM-1 expression, preventing inflammatory infiltration at the level of the microvasculature
and leading to accumulation of mononuclear cells within
the meninges.
To determine whether CXCR7 antagonism affected the
percentages and overall numbers of mononuclear subsets
within the spinal cord parenchyma, we performed flow cytometric analyses of cells isolated from spinal cord tissues of vehicle
and CCX771-treated (10 mg/kg) mice at the peak of disease.
CXCR7 antagonism led to a decrease in both the percentages
and total cell numbers of infiltrating CD4+, CD11b+, and B220+
cells (Fig. 4, e and f). Analysis of CD45+CD11b+ popula
tions revealed significant decreases in both activated microglia
(CD45hiCD11blow) and macrophages (CD45hiCD11bhi; Fig. 4 f).
Vehicle-exposed versus CCX771-exposed MOG-specific T cell
JEM VOL. 208, February 14, 2011

lines exhibited identical levels of proliferation and cytokine
expression during antigen-specific reactivation in vitro (Fig. S3).
Analysis of cytokine expression within the spinal cord tissues
of vehicle versus CCX771-treated mice at the peak of disease
revealed no differences in levels of T cell cytokines (Fig. S4 a),
suggesting that T cells within both meningeal and parenchymal compartments express similar levels of proinflammatory
cytokines. Collectively, these data indicate that CXCR7 antagonism ameliorates EAE by preventing the parenchymal
entry of leukocytes specifically via effects at the CNS microvasculature and that this limits the overall trafficking and
entry of leukocytes to the CNS.
T cell cytokines regulate internalization of CXCL12 by brain
endothelial cells via CXCR7
Previous studies showed that T cell–derived IL-1 contributes to leukocyte CNS entry and disease severity during
EAE via loss of abluminal CXCL12 at the BBB (McCandless
et al., 2009). CXCL12 removal from cell surfaces may occur in
mammalian systems via CXCR7-mediated trafficking to lyso
somes for degradation (Luker et al., 2010). Thus, we wondered whether various T cell cytokines might contribute to
leukocyte egress through alterations in the expression or sequestration of CXCL12, with the latter occurring via regulation of the expression and/or activity of CXCR7. To test this
331
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Figure 3. CXCR7 antagonism prevents
leukocyte entry at the microvasculature.
(a) Histological analyses of spinal cord tissues
from vehicle- and CCX771-treated (10 or 30
mg/kg) mice 12 d after MOG-specific CD4+
T cell transfer. Note perivascular cuffs in vehicle
treated tissue section (arrows). Bars, 25 µm.
(b) IHC and confocal imaging detection of
GFAP (red) and VCAM-1 (green) within meninges (top images) and white matter (bottom
images) of animals with EAE treated with vehicle
(left) versus CCX771 at 10 or 30 mg/kg. Nuclei
were counterstained with ToPro3 (blue).
(inset) Isotype control (IC). Higher magnification
images of boxed areas on lower power images
of meninges from mice treated with vehicle
and 10 mg/kg CCX771 are provided to the right
of merged images. Note the lack of astrocyte
but not meningeal (arrowheads) expression of
VCAM-1 in CCX771-treated tissues. Analyses
were performed on spinal cords harvested
from three animals per group at peak of disease. Bars, 25 µm. Quantitation of meningeal
width (c), lesion number (d), and lesion characteristics (e) in mice from four treatment
groups: none (white bars), vehicle (light gray
bars), CCX771 at 5 mg/kg (dark gray bars), and
10 mg/kg (black bars). Scoring of perivascular
cuffs: 1 = 2–6 cells; 2 = 6–11 cells; 3 > 11 cells.
n = 5 mice/group; data expressed as mean
width (millimeters; c), number of white matter
(WM) lesions (d), or number of lesions of each
score (e) ± SEM. *, P < 0.05.
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directly, we evaluated brain endothelial cell responses to T cell
cytokines relevant to altered BBB during CNS autoimmunity. Primary brain microvessel endothelial cells (BMECs)

treated with various doses of IL-17, IL-1, IFN-, and TNF
were evaluated for expression of CXCL12, CXCR4, and
CXCR7 and the lysosomal-associated membrane protein

Downloaded from jem.rupress.org on September 13, 2011
Figure 4. CXCR7 antagonism limits leukocyte trafficking to the CNS. IHC analyses of infiltrating leukocytes expressing CD3, CD11b, or B220 in
respect to activated astrocytes (red, GFAP) within the meninges (a) and white matter (b) of vehicle-treated versus CCX771-treated (10 or 30 mg/kg) mice
with EAE. Nuclei were counterstained with ToPro3 (blue). Bar, 10 µm. Analyses were performed on spinal cords harvested from three animals per group at
peak of disease. (c) Quantitative analysis of numbers of white matter lesions attributed to the infiltration of CD3+, CD11b+, and B220+ cells within spinal
cord tissues of vehicle-treated and CCX771-treated (10 or 30 mg/kg) mice with EAE. Data are presented as the mean numbers of lesions in n = 3 mice per
group ± SEM. (d) IHC analysis of infiltrating leukocytes (red, CD45) in respect to TNF expression (green) in spinal cords of vehicle-treated versus CCX771treated (10 mg/kg) mice with EAE. Nuclei were counterstained with ToPro3 (blue). Bar, 25 µm. (e and f) Flow cytometric analysis of percentages (e, numbers in quadrants) and total cell numbers (f) of CD4+, CD8+, CD45+, CD11b+, CD11c+, and B220+ leukocytes harvested from spinal cords of vehicle-treated
versus CCX771-treated (10 mg/kg) mice. Data depicting total cell numbers are presented as the mean numbers of cells derived from spinal cords of
vehicle-treated versus CCX771-treated mice with EAE ± SEM from three experiments with five mice per group. *, P < 0.05; **, P < 0.01.
332
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Figure 5. CXCR7 expression and CXCL12 internalization are altered by T cell cytokines. (a) Primary BMECs were treated with indicated doses of IL-17, IL-1,
IFN-, and TNF, and expression of CXCL12, CXCR4, CXCR7, LAMP-1, and LAMP-2 mRNA were measured via QPCR. Data from three experiments with triplicates are
presented as the mean fold change in mRNA levels over untreated controls ± SEM. *, P < 0.05; **, P < 0.001. (b) BMECs derived from CXCR7GFP/+ mice were treated with
cytokines (IL-1, IL-17, IFN-, and TNF) or VEGF (100 ng/ml) or left untreated (control), and CD31 (red) and GFP (green) expression was evaluated. Nuclei counterstained with ToPro3 (blue). Bar, 10 µm. (c) Quantitative analysis of GFP expression in cytokine- or VEGF-treated CD31+ CXCR7GFP/+BMECs. Data from three experiments
performed in triplicate and presented as the mean fold change in GFP expression over untreated BMECs ± SEM. *, P < 0.05; **, P < 0.001. (d) LAMP-1 (green) and
CXCL12 (red) colocalization in BMECs left untreated (control) or treated with IFN-, IL-1, and IL-17. Bar, 10 µm. (e) Quantitation of CXCL12 and colocalization of
CXCL12 and LAMP-1 staining in control and IL-1–, IL-17–, and IFN-–treated BMECs. Data from three experiments in which five images were analyzed in each of
three replicates per treatment group and presented as mean fold change over untreated controls. *, P < 0.05; **, P < 0.001.
JEM VOL. 208, February 14, 2011
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identify vessels with abluminal CXCL12 observed in naive
animals and lack of CXCL12 at sites of lesions in mice with
adoptive transfer EAE (Fig. S5 b).Thus, to determine whether
CXCR7 antagonism altered the BBB expression of CXCL12
in vivo, we analyzed the kinetics of CXCL12 removal at the
CNS vasculature at various time-points posttransfer of encephalitogenic T cells. Similar amounts of abluminal CXCL12 around
CD31+ postcapillary venules was observed in the spinal cords
of mice from both treatment groups at day 2 after transfer of
MOG-specific T cells, but was completely absent by day 8 in
mice treated with vehicle. Animals treated with CXCR7 antagonist (10 mg/kg) exhibited persistent abluminal CXCL12
until 10 d after transfer (Fig. 6, d and e). Analysis of panCXCL12
mRNA levels in IL-1–treated BMECs exposed to vehicle
versus CCX771 and CXCL12 (Stumm et al., 2002) mRNA
levels in spinal cords derived from mice at peak clinical disease (day 10) revealed no effects of antagonist on CXCL12
expression (Fig. S6), suggesting that the increased CXCL12
protein observed during CXCR7 antagonism is caused by
blockade of its internalization by CNS endothelium.
DISCUSSION
The current study provides compelling evidence that
CXCR7-mediated internalization of CXCL12 is critical for
the parenchymal infiltration of autoreactive leukocytes during
CNS autoimmunity and that IL-17, IFN-, and IL-1 regulate this process via alterations in CNS endothelial cell expression of CXCL12 and CXCR7. This is supported by both
in vitro and in vivo experiments in which CXCR7 antagonism prevented the endothelial cell internalization and lysosomal delivery of CXCL12, leading to increased extracellular
levels of the chemokine. In vitro, endothelial cell internalization of CXCL12 was augmented by treatment with IL-17
and IL-1, decreased by IFN-, and completely blocked by
CXCR7 antagonism. In vivo, endothelial cell CXCR7, which
was detected exclusively at post-capillary venules within
murine CNS tissues, exhibited increased expression at this
location in specimens derived from mice with EAE induced
by the adoptive transfer of MOG-specific T cells. Most strikingly, administration of a CXCR7 antagonist during induction of EAE led to a dose-dependent inhibition of disease
severity and promotion of recovery and complete amelioration of symptoms when administered to mice during ongoing disease. The in vivo effect of CXCR7 antagonism during
EAE was associated with inhibition of leukocyte trafficking
from leptomeningeal vessels to the microvasculature, leading
to a significant widening of meningeal infiltrates and a significant decrease in the numbers and extents of parenchymal
infiltrates. This latter effect of CXCR7 antagonism was also
associated with a complete loss of VCAM-1 up-regulation
by spinal cord astrocytes, an essential step in the parenchymal
entry of leukocytes during EAE (Gimenez et al., 2004).These
are the first in vivo data demonstrating a role for CXCR7mediated internalization of CXCL12 in an autoimmune disease, identifying the receptor as a putative therapeutic target
for MS.
CXCR7 controls leukocyte trafficking into CNS | Cruz-Orengo et al.
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(LAMP)-1 and LAMP-2, which are components and mark
ers of the lysosomal membrane, via quantitative RT-PCR
(QPCR; Fig. 5 a). IL-17 led to a significant increase in
CXCR7 mRNA levels (P = 0.025), whereas both IL-1 and
IFN- led to dose-dependent decreases in the mRNA levels
of both CXCR4 and CXCR7 (P < 0.01 for all comparisons;
Fig. 5 a, top and bottom). Similarly, BMECs derived from
CXCR7GFP/+ mice treated with high doses of cytokine and
assessed for changes in GFP expression via quantitative confocal microscopic analysis exhibited significantly increased
GFP expression after treatment with IL-17 (P = 0.013) and
decreased GFP expression after treatment with IFN- (P =
0.0003; Fig. 5, b and c). In contrast with the QPCR results,
levels of GFP expression were not affected by IL-1, but were
decreased by treatment with TNF (P = 0.015; Fig. 5, a–c).
BMEC CXCL12 expression was significantly increased by
treatment with either IL-1 (P = 0.0006) or TNF (P = 0.005;
Fig. 5 a, right top and bottom), but was decreased by treatment with IFN- (P = 0.019; Fig. 5 a, bottom left). LAMP-1
and LAMP-2 mRNA levels were not significantly altered by
cytokines (Fig. 5 a). Colocalization of CXCL12 and LAMP-1
within BMECs, as assessed by confocal IHC analysis, was significantly increased by treatment with IL-17 (P = 0.014) or
IL-1 (P = 0.0007; Fig. 5, d and e), whereas treatment with
IFN- decreased CXCL12 internalization.
To specifically analyze the sequestration of extracellular
CXCL12, we evaluated cytokine-mediated uptake of exogenous fluorescent CXCL12-mCherry fusion protein via confocal IHC. This fusion protein exhibits CXCR4-binding
kinetics and signaling comparable to unfused CXCL12 and
has been used to quantify inhibition of CXCR7 binding by
antagonists (Luker et al., 2009; Naumann et al., 2010). Exposure of BMECs to 300 ng/ml CXCL12-mCherry, but not
mCherry alone, leads to colocalization of the fusion protein
with LAMP-1 (Fig. 6 a). Analysis of BMECs treated with
IL-1 (P < 0.0001) and IL-17 (P < 0.0001) revealed significant increases in CXCL12-mCherry internalization over
those left untreated or treated with IFN- (Fig. 6, a and b).
Internalization of CXCL12-mCherry in IL-1–treated (P =
0.002) or IL-17–treated (P = 0.016) BMECs exhibited dosedependent inhibition by CCX771 (Fig. 6 c), indicating that
this process is mediated by CXCR7. Consistent with this,
examination of CXCL12-mCherry internalization within
lysosomes in BMECs exposed to a neutralizing, anti-CXCR4
antibody did not demonstrate a role for CXCR4 in this process (Fig. S4 b).Taken altogether, these data indicate that T cell
cytokines regulate the levels of extracellular CXCL12 via effects on the expression of chemokine or on expression or activ
ity of CXCR7.
Endothelial cell internalization of CXCL12 leads to its
colocalization with CD31 in spinal cord postcapillary venules in
mice with EAE induced by active immunization (McCandless
et al., 2006), whereas mice with adoptive transfer EAE exhibit
complete loss of CXCL12 at this site (Fig. S5 a). Use of
CXCR7GFP/+ mice to evaluate CXCL12 expression patterns
revealed similar results as those observed using CD31 to
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Several studies suggest that CXCR7 primarily functions
to internalize CXCL12 to efficiently transduce changes in
chemokine gene expression, and thereby stringently regulate
CXCR4 signaling. Although this function has been well
characterized during zebrafish development (Valentin et al.,
2007; Boldajipour et al., 2008), recent in vitro studies suggest
CXCR7 also sequesters CXCL12 in mammals (Luker et al.,
2010; Naumann et al., 2010). Consistent with this function,

CXCR7 cycles continuously between the cell surface and
endosomal compartments and is rapidly replenished from intracellular stores after ligand-induced internalization (Naumann
et al., 2010). In the normal adult brain, CXCR7 mRNA is
expressed by neurons and endothelial cells (Schönemeier
et al., 2008a). Although factors that regulate CXCR7 mRNA
expression within the CNS endothelium are unknown, they
are likely to involve inflammatory pathways, as permanent
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Figure 6. BMEC internalization of CXCL12 is mediated by CXCR7. (a) BMECs were left untreated (control) or treated overnight with IL-1 (10 ng/ml),
IL-17 (100 ng/ml), or IFN- (100 ng/ml) and internalization of CXCL12-Cherry (red, L12mCherry; left) versus mCherry alone (inset) via colocalization with
LAMP-1 (green). Nuclei were counterstained with ToPro3 (blue) Magnification 40×. Bar, 20 µm. (b) Fold changes in internalization of CXCL12-Cherry in
BMECs treated with IL-1 (10 ng/ml), IL-17 (100 ng/ml), or IFN- (100 ng/ml) over those left untreated. (c) Fold changes in internalization of CXCL12Cherry in IL-1– and IL-17–treated BMECs left unexposed or exposed to 10 nM or 100 nM (filled bars) CCX771. All quantitative data are presented as
mean ± SEM for an experiment done in triplicate, and are representative of three to four experiments. **, P < 0.001; *, P < 0.05. (d) Detection of CD31
(green) and CXCL12 (red) within spinal cords of mice treated with vehicle or CCX771 (10 mg/kg for all bottom panels except for the far right panel, which
is from a mouse treated with 30 mg/kg) at 2, 4, 6, 8, and 10 d after transfer of MOG-specific CD4+ T cells. Nuclei have been counterstained with Topro3
(blue). Bar, 20 µm. IC, isotype control. Data are representative of 10 images each from 3 mice per treatment group per time point. (e) Quantitative analysis
of CXCL12 expression on CD31+ venules within the spinal cords of mice at various days after transfer of MOG-specific T cells. Data derived from venules
analyzed within four to eight images per spinal cord for three mice per treatment group for each time point, and are expressed as the mean ratios of
signal intensity of CXCL12/CD31 ± SEM. **, P < 0.001 and *, P < 0.05 for comparisons between treatment groups on the same day after transfer; #, P < 0.05
for comparisons between days 2 and 8 after transfer within a treatment group.
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for the development of novel therapies for this disease. However, the targeting of molecules expressed by immune cells
may not be specific for the CNS, as natalizumab also targets
gastrointestinal-homing lymphocytes (Baron et al., 1993).
In addition, natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML), an opportunistic,
fatal encephalitis caused by JC virus (Clifford, 2008). Our data
indicate that targeting CXCR7 specifically inhibits lymphocyte entry into the CNS via effects on the CNS microvasculature in both the meningeal and parenchymal compartments.
The lack of inflammation at high doses of CCX771 suggests
that CXCR7 is required for entry of cells into the meningeal
compartment, which is the first site of leukocyte accumulation during neuroinflammation. Thus, low-dose CCX771
partially blocked leukocyte recruitment, allowing meningeal
accumulation, whereas high-dose CCX771 completely abrogated leukocyte localization at both sites. In addition, CXCR7
antagonism prevented lymphocyte egress via persistent BBB
expression of CXCL12, effectively diminishing parenchymal
responses to T cell cytokines, such as TNF, which are required
for astrocyte expression of VCAM-1 (Gimenez et al., 2004).
Studies examining CXCR7 antagonism in the contexts of
acute and chronic CNS infections will reveal additional insights regarding the safety of this approach.
In summary, our study provides evidence that CXCR7mediated sequestration of CXCL12 at the CNS vasculature
regulates leukocyte localization at this site during CNS autoimmunity. We also provide evidence that the differential responses of CNS regions to varying ratios of Th1 versus Th17
cells during induction of autoimmunity may be caused by
opposing effects of IFN- and IL-17 on BBB CXCR7 expression. Thus, the ubiquitous expression of CXCR7 at CNS
postcapillary venules may provide a molecular switch that preserves or destroys barriers to leukocyte entry, depending on
the cytokine milieu. Targeting CXCR7 may therefore provide additional specificity for the prevention of lymphocyte
egress regardless of the cytokine profile associated with disease expression (Axtell et al., 2010).
MATERIALS AND METHODS
Animals and antibodies. C57BL/6 (The Jackson Laboratory) and
CXCR7GFP/+ mice were maintained in pathogen-free conditions (Department of Comparative Medicine, Washington University, St. Louis, MO), and
studies were performed in compliance with the guidelines of the Washington
University School of Medicine Animal Safety Committee. Antibodies used
include CXCL12 rabbit polyclonal (PeproTech), actin antibodies (SigmaAldrich), IgG isotype (Jackson ImmunoResearch Laboratories), monoclonal
rat anti–mouse-CD31, CD11b, Thy1.1, VCAM-1 (BD), anti-CD3 (Dako),
anti-B220 (R&D Systems), GFAP (Zymed), LAMP-1 (US Biologicals), GFP
(Invitrogen), and fluorescently conjugated antibodies against CD4, CD8,
CD19, CD11b, CD11c, B220, and CD45 (BD).
Generation of CXCR7 knock-in mice. The entire open reading frame
of Cxcr7 gene encoded by exon 2 was replaced by EGFP sequence. A 5 homology arm containing a 5.4-kb genomic fragment containing part of intron
1 and 26 bp of exon 2 immediately upstream of the ATG start codon was
PCR amplified using C57BL/6 genomic DNA as templates, and then cloned
in front of EGFP coding sequence. A 3 homology arm containing a 5.2-kb
CXCR7 controls leukocyte trafficking into CNS | Cruz-Orengo et al.
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middle cerebral artery occlusion leads to increased CXCR7
mRNA within vascular elements of the ipsilateral cortex
(Schönemeier et al., 2008b). Consistent with this, we observed increased levels of expression of CXCR7 along the
microvasculature during EAE and after in vitro treatment of
BMECs with IL-17, a T cell cytokine implicated in the trafficking of immune cells into the CNS parenchyma (Kebir
et al., 2007; Fabis et al., 2008; Huppert et al., 2010). IL-17 and
IL-1, another cytokine implicated in T cell entry early in the
course of EAE (Sutton et al., 2006), also promoted the internalization of CXCL12 and its colocalization with LAMP-1
within BMECs, supporting the notion that proinflammatory
cytokines regulate localizing molecules at the BBB. IFN-,
however, decreased BMEC expression of CXCL12, CXCR4,
and CXCR7. These results are consistent with prior reports
that IFN- down-regulates CXCR4 in neutrophils and the
homeostatic chemokines CXCL13 and CCL21 in lymphoid
tissues (Nagase et al., 2002; Mueller et al., 2007). Thus, although CXCR7 and CXCL12 likely exist in equilibrium
under homeostatic conditions, preserving localizing cues that
slow leukocyte egress into the parenchyma, inflammatory cyto
kines may differentially shift this equilibrium in favor of preventing or promoting leukocyte entry.
Studies examining the role of T cell cytokines in the location of inflammatory lesions during EAE have determined that
IL-17 is also essential for brainstem inflammation (Kroenke
et al., 2010). In our study, levels of CXCR7 in all white matter
regions were similar in naive mice whereas mice with EAE
exhibited significant increases in CXCR7 expression in spinal
cord and cerebellum. In contrast, levels of CXCR7 expression remained unchanged from baseline with the brainstem,
a CNS region that typically does not develop any inflammatory lesions in classical EAE models. Of interest, transfer
of MOG-specific T cells that express high levels of IL-17
induce more brain inflammation and atypical EAE (Stromnes
et al., 2008). Our data demonstrating that high levels of
IL-17 induce CXCR7 expression in BMECs suggest that this
cytokine may differentially affect leukocyte entry in various
CNS regions through effects on CXCR7-mediated internalization of CXCL12 at the microvasculature. Further studies
using tissue-specific transgenic approaches are planned to further define the in vivo effects of Th17 cells on CXCR7,
CXCR4, and CXCL12 location and activity at the BBB during
EAE. Although we did not detect CXCR7 expression by infiltrating leukocytes within the CNS, we did identify a subpopulation of CD19+ cells that expressed CXCR7 within
lymphoid tissues in MOG-immunized animals.Thus, CXCR7
may play a role in the early adaptive immune responses of B
cells, as suggested by a previous study (Infantino et al., 2006).
Infiltrating, autoreactive leukocytes require binding of integrin 41 (VLA-4) to VCAM-1 for entry into CNS parenchyma (Yednock et al., 1992; Baron et al., 1993). The success
of natalizumab, a humanized monoclonal antibody against
4-integrin, in preventing new lesion formation in MS patients (Belachew et al., 2011) indicates that targeting molecules involved in leukocyte entry is indeed a tractable approach
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genomic fragment including DNA sequence immediately downstream of
stop codon of Cxcr7 gene was PCR amplified using C57BL/6 genomic
DNA and cloned after a neomycin-resistant gene cassette flanked by Lox P
sites. The sequence of the targeting construct was confirmed by DNA sequencing.The targeting construct was linearized by Not I restriction enzyme
and electroporated into albino C57BL/6 embryonic stem (ES) cells.The colonies doubly resistant for the aminoglycoside G418 and ganciclovir were
screened by Southern blot analyses with BsrgI, BamHI, and HindIII digestions for homologous recombination. Positive clones were injected into
mouse blastocysts. Mice were subsequently crossed with EIIa-cre to remove
the neomycin-resistant cassette.

Assessment of plasma concentrations of CCX771. A total of 12 male
BALB/c mice (The Jackson Laboratory) were administered a subcutaneous
injection of 10 mg/kg CCX771, formulated as a solution in 10% Captisol
with dosing volume at 1 ml/kg. Plasma samples were obtained from retro
orbital obtained blood (100 l) collected into EDTA tubes at determined time
points. Each animal was bled only twice during the study; thus, each timepoint reflects data from three of the animals on study. After protein precipitation, the supernatant solutions were analyzed by HPLC-MS/MS using a
validated method (nominal plasma concentration; range from 1 to 1,000 ng/ml).
Pharmacokinetic values for CCX771 were generated using noncompartmental analysis with WinNonlin Professional version 5.2 (Pharsight).
EAE induction and in vivo treatment with CCX771. Active EAE was
induced in 8–12-wk-old female C57BL/6 (The Jackson Laboratory) mice
by subcutaneous immunization with murine myelin oligodendroglial glycoprotein peptide 35–55 (MOG; Sigma-Aldrich) and followed for clinical
disease as previously described. MOG-specific T cells were generated as previously described (Gimenez et al., 2004). Activated cells were collected and
transferred retroorbitally at 107 cells per mouse. Mice from all experiments
were graded for clinical manifestations of EAE by the following criteria: 1,
tail weakness; 2, difficulty righting; 3, hindlimb paralysis; 4, forelimb weakness
or paralysis; 5, moribund or dead. CCX771 (ChemoCentryx) or vehicle
(10% Captisol) was administered daily to mice subcutaneously at doses of 5,
10, or 30 mg/kg in 100 ml of vehicle at the time of adoptive transfer of T cells
or when mice achieved a clinical score of 1.
LFB staining of spinal cord. Frozen sections were stained for myelin using
0.1% LFB and counter stained with 0.1% cresyl violet.The sections were differentiated with 0.5% lithium carbonate, counterstained with cresyl violet for
20 min, and mounted for imaging using an Axioskop 40 light microscope
(Carl Zeiss, Inc.).
Assays of T cell proliferation and cytokine expression. MOG-specific
T cell lines underwent three 7-d rounds of restimulation in the presence of
irradiated splenocytes (ratio 1:5), 0.01 mg/ml MOGp35-55, and IL-2, IL-12,
JEM VOL. 208, February 14, 2011

QPCR analysis of spinal cord expression. Total RNA was prepared and
QPCR was performed as previously described (Klein et al., 2005) using
primers for TNF, IFN-, IL-10, IL-17, and IL-1, whose sequences have
been previously published (Klein et al., 2004, 2005).
Preparation of murine BMECs. Murine BMECs were generated using
previously described methods (Perrière et al., 2005), with slight modifications. In brief, cortices of 8-wk-old C57BL/6J mice were dissected free of
meninges, minced, and digested with 1 mg/ml collagenase CLS2 (Worthington) and 30 U/ml DNase (Sigma-Aldrich) at 37°C for 45 min, with shaking.
The digested cell pellet was separated by centrifugation in 20% BSA in DME
(1,000 g for 20 min), followed by a further digestion in 1 mg/ml collagenasedispase (Roche) and 10 U/ml DNase at 37°C for 30 min, with shaking.
Microvessel fragments were subsequently isolated on a 33% continuous Percoll gradient (1,000 g for 10 min), washed twice with DME, and plated to
T-25 flasks coated with 0.1 mg/ml mouse collagen type IV and 0.1 mg/ml
human fibronectin.
BMEC expression of CXCR7. Primary BMECs were treated with various concentrations of IL-17, IL-1, TNF, and IFN-g or left untreated for 24 h
before undergoing total RNA isolation, as previously described (McCandless
et al., 2006). QPCR analysis of CXCR7 was accomplished using a Taqman gene expression assay kit (Applied Biosystems), which uses the FAM/
TAMRA reporter with primers spanning the first and second exon and amplifies a 77-bp product. Calculated copies were normalized against copies of
the housekeeping gene GAPDH.
Histological, IHC, and immunocytochemical analyses. Murine CNS
tissues were isolated and frozen sections were permeabilized, blocked, and
stained as previously described (McCandless et al., 2006). Histological analyses, including myelin staining and IHC detection of CD31, CXCL12,
VCAM-1, TNF, GFAP, CD3, and CD11b with nuclear ToPro3 counterstaining, were performed as previously described (Gimenez et al., 2004; McCandless
et al., 2008b).
Colocalization of CXCL12 and LAMP-1 within primary BMECs was
performed after fixation with 4% paraformaldehyde for 10 min and permeabilization with block in 0.1% Triton X-100 and 10% goat serum for 30 min
at room temperature. BMECs were incubated with the primary antibodies
rabbit anti–human CXCL12 (PeproTech, 1:20) and rat anti–mouse LAMP-1
(1:50; US Biologicals) in blocking buffer for 20 min at room temperature.
Cells were washed three times in PBS, and then incubated in fluorescently
conjugated goat anti–rabbit Alexa Fluor 555 and goat anti–rat Alexa Fluor
488 (1:1,000; Invitrogen) secondary antibodies in blocking buffer for 15 min
at room temperature. Cells were washed, counterstained with ToPro3, and
coverslipped before being visualized on the confocal microscope and accompanying software.
Flow cytometry. Cells were isolated from the draining lymph nodes,
spleens, and spinal cords of MOG-immunized CXCR7GFP/+ or C57BL/6
mice at 9 d after immunization and stained with fluorescently conjugated
antibodies to CD4, CD8, CD19, CD11b, CD11c, and CD45 as previously
described (McCandless et al., 2006). Removal of spinal cords was accomplished
337
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Analysis of CCX771 selectivity. Human neutrophils were isolated from
whole blood and lymphocytes from buffy coats (Stanford Blood Center,
Stanford, CA) via Ficoll-Paque PLUS centrifugation followed by red blood
cell lysis. Lymphocyte fractions were activated in vitro, as previously described (Walters et al., 2010). CEM, Molt-4, and U937 cells were obtained
from American Type Culture Collection (ATCC) and cultured in RPMI1640 medium (Sigma-Aldrich) supplemented with 10% FBS. U937 cells
were additionally treated with dibutyryl cyclic-AMP (Sigma-Aldrich). Baf3
and L1.2 cells (ATCC) were stably transfected with human CCR5 and
ChemR23, respectively, and were cultured in RPMI-1640 medium/10%
FBS supplemented with murine IL-3. Chemokines were purchased from
R&D Systems. Calcium flux, chemotaxis, and radioligand binding assays
were all performed as previously described (Zabel et al., 2009; Walters et al.,
2010). Analysis of CCX771 activity against a panel of G protein–coupled receptors (GPCRs;Table S2) was conducted under contract by Cerep using the
Non-Peptide Receptor Express Profile option (http://www.cerep.fr/cerep/
users/pages/downloads/pharmacology.asp).

and anti-IL-4, as previously described (Gimenez et al., 2006). During the
third restimulation,T cells were treated for 4 d with various doses of CCX771
(ChemoCentryx) versus vehicle (DMSO) or CCX704, an inactive CXCR7
antagonist, and then evaluated for proliferation and cytokine expression. For
proliferation responses,T cells were preloaded with CFSE (Invitrogen) before
third restimulation. For cytokine responses, supernatants of restimulated cells
were evaluated for Th1/Th2/Th17 cytokine expression via cytokine bead
array (BD). Data acquisition for CFSE labeling and cytokine expression panel
was performed via BD FACSCalibur flow cytometry and analyzed by BD
FCAP Array software.
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via pressure-syringing using an 18 gauge needle. Data collection and analysis
were conducted using a FACSCalibur flow cytometer using CellQuest software (BD), as previously described (McCandless et al., 2009).
Generation of mCherryCXCL12 and internalization experiments.
mCherry plasmid DNA was used to transfect 293T cells as previously described (Luker et al., 2009). Supernatants containing mCherry-CXCL12
were collected 24 h after transfection. To assess mCherry CXCL12 uptake,
BMECs were treated with IL-17 (100 ng/ml), IL-1 (10 ng/ml), IFN- (100
ng/ml) or control media for 24 h in media containing vehicle, CXCR7 antagonist, CCX771, or anti-CXCR4 antibody (R&D Systems). BMECs were
incubated for 2 h with mCherry-CXCL12 supernatants, and then fixed with
ice-cold methanol for 10 min. Cells were then counterstained with ToPro3
and visualized immediately, or further stained with LAMP-1 as described in
Histological, IHC, and immunocytochemical analyses.

Online supplemental material. Fig. S1 depicts the generation of CXCR7
GFP knock-in mice. Fig. S2 shows that CXCR7 antagonism prevents demyelination during EAE. Fig. S3 shows that CXCR7 antagonism does not affect
MOG-specific T cell reactivation. Fig. S4 shows cytokine levels within spinal
cord parenchyma in mice treated with vehicle versus CXCR7 antagonist and
that BMEC internalization of CXCL12 does not require CXCR4. Fig. S5
depicts abluminal CXCL12 at post-capillary venules during EAE induced
by adoptive transfer of MOG-specific CD4+ T cells and immunization with
MOG. Fig. S6 shows that CXCR7 antagonism does not alter CXCL12
mRNA levels in BMECs or in spinal cords of mice with EAE.
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